We chose the serine protease family as an ideal group of targets to demonstrate our strategy mainly because inhibiting the human serine proteases is of clinical value: both KLK6 and mesotrypsin are involved in cancer progression57–59, while anionic and cationic trypsins are involved in the etiology of pancreatitis60,61. Here, PRSS3 is linked to cancer.